Latest news with #LMU
Hans India
4 hours ago
- Politics
- Hans India
Won't demolish slums, dwellers are city's lifeline: Delhi CM Rekha Gupta
New Delhi: Describing slum dwellers as service providers and the lifeline of Delhi, Chief Minister Rekha Gupta on Saturday assured that no slum colonies in the city will be demolished without rehabilitation. She also announced that Rs 700 crore has been allocated for carrying out development works like toilets and washrooms for women in slums. In a special conversation hosted by actor Anupam Kher at the '100 Din Sewa Ke' event organised at Jawaharlal Nehru Stadium to mark 100 days of the BJP government, CM Gupta sympathised with slum dwellers in the city, saying, 'None of the previous governments really cared for them. They have been living in slums for decades.' Dismissing rumours spread by the opposition regarding slum demolitions, she said, 'Unless every slum dweller receives a permanent home, they will continue to live in their current shelter — but with improved facilities and dignity.' Criticising the previous AAP government and its false promises, CM Gupta said, 'While they sat in Sheeshmahal, we have rebuilt Delhi with honesty.' She also highlighted how the PM-JAY health insurance scheme was approved in the very first Cabinet meeting. On the health front, the CM said, the Ayushman Bharat Digital Mission has also been implemented across hospitals, where Jan Aushadhi Kendras are being set up. Further, advanced healthcare units such as LMU, NAT testing, and a medical genetics ward have been established at Lok Nayak Hospital, ensuring high-quality care. Talking about achievements in the education sector, she said, 'While previous governments only focused on publicity, we approved the Delhi School Education (Transparency in Fixation & Regulation of Fees) Bill 2025 to end the arbitrariness of private schools.' The CM also hit out at the previous AAP government for leaving behind mountains of waste, turning Delhi into a landfill. She said her government has taken concrete steps to eliminate these legacy waste sites, as 24x7 legacy waste processing has been started, with about 30,000 metric tonnes of garbage being biomined daily. 'Waste-to-energy plant installations are progressing swiftly. The target is to completely remove the Bhalaswa and Okhla landfill sites within the next two years,' she said. Currently, Delhi has four operational waste-to-energy plants, and two new plants in Narela and Ghazipur are under rapid construction. Expansions of the Okhla and Tehkhand plants are also underway. Moreover, a modern e-waste park is being developed in Holambi Kalan, she said. Talking about environmental protection, CM Gupta criticised the previous government for turning Delhi into a gas chamber. In contrast, she said, her government has prioritised pollution control by deploying 1,000 sprinklers throughout the year and approving 70 advanced mechanical road sweeping machines. 'Installation of smog guns in all high-rise buildings has also been made mandatory. Additionally, under the DEVi (Delhi Electric Vehicle Interconnector) initiative, 460 electric buses have been introduced for last-mile connectivity, and 2,000 more electric buses will be added by the end of the year,' she said. On the Yamuna River, the CM highlighted that the previous government merely put up a show in the name of cleaning the river, while untreated sewage continued to flow into it. In contrast, her government made the rejuvenation of Yamuna a top priority from day one, she said.
The Hindu
2 days ago
- Health
- The Hindu
City's first medical genetics dept. set up in LNJP Hospital; CM inaugurates unit
Delhi's first Medical Genetics department and the fourth such unit in the country has been set up in the Lok Nayak Jai Prakash Narayan (LNJP) Hospital. While inaugurating the department on Thursday, CM Rekha Gupta said, 'There are lakhs of parents scrambling to save their children who are born with genetic disorders. They do not know where to go. This department will treat those children who are born with such disorders.' Ms. Gupta also inaugurated a Lactation Management Unit (LMU), and Nucleic Acid Amplification Testing (NAT) Lab in the hospital. Regarding the Lactation Management Unit (LMU), she said that the unit is designed to serve preterm, low-birth-weight, and critically ill new-borns. It will offer breastfeeding counselling, safe milk collection and storage, and hospital-grade breast pumps for mothers. 'Our goal is to ensure accessible, high-quality, and timely medical services for every citizen—regardless of age, background, or region. A healthy Delhi is the foundation of a developed Delhi. With this vision, three highly advanced health services have been launched, setting a new milestone in the city's medical infrastructure,' Ms. Gupta said. This is the first Delhi government hospital to have a NAT Lab, she said, adding that screening reports, which used to take 45 days, will be available within two days here. The NAT is a highly sensitive diagnostic method capable of detecting viral infections like HIV, Hepatitis B, and C at an early stage. The CM also criticised the state of the healthcare infrastructure that the BJP government inherited from previous government, calling it 'deeply concerning.' She added that while the World Health Organisation recommends a minimum of two beds per 1,000 population, not even one bed per 1,000 citizens is available in the Capital. She said that the Delhi government aims to ensure at least three beds per 1,000 people within the next five years.
![Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fapnews.com.png&w=48&q=75){kind=small}
Associated Press
20-05-2025
- Health
- Associated Press
Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation
Joining forces to accelerate development and to create a potential new option for Neuroinflammation Imaging BERLIN and BOSTON, May 20, 2025 /PRNewswire/ -- Life Molecular Imaging has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance significant research in Alzheimer's disease (AD). The $2.16 million investment, spanning three years, will fuel the development of [18F]F‑DED, an investigational F18-labeled PET imaging agent designed to target monoamine oxidase B (MAO-B), a key enzyme linked to neuroinflammation. This ambitious research initiative is a collaborative effort with two world-class institutions, including the University Hospital of Ludwig-Maximilian University (LMU; Munich, Germany) and the Barcelona Beta Brain Research Center (BBRC, Spain), with experts in neurology, nuclear medicine, psychiatry, and stroke and dementia research. It is anticipated that using [18F]F-DED PET imaging during this project has the potential to provide critical insights into both sporadic and genetically predisposed AD patients, bridging the gap on the contribution of neuroinflammation between early and late stages of the disease. Until now, PET imaging of neuroinflammation has faced challenges due to genetic polymorphisms affecting ligand binding, leading to inconsistent results. 'This new research, supported by the prestigious ADDF funding, provides a unique opportunity to investigate the spatial and temporal dynamics of neuroinflammation and its association with established biomarkers,' said Andrew Stephens, Chief Medical Officer at LMI. 'Neuroinflammation could be a potential key driver in the spread of tau pathology to the cortex in Alzheimer's disease. Leveraging PET imaging to explore its role presents a unique opportunity to deepen our understanding of disease progression,' added Matthias Brendel, Professor for Nuclear Medicine at LMU. Gemma Salvadó Blasco, Group Leader of Neuroimaging Research BBRC, echoed this enthusiasm: 'By combining data from diverse Alzheimer's disease cohorts, we aim to unravel the complexities of disease progression. We're thrilled to embark on this exciting journey.' 'PET-Imaging tools provide important insights into understanding Alzheimer's disease and other neurodegenerative disorders and are integrated now into clinical care,' says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. 'New imaging tools exploring neuroinflammation may offer a non-invasive approach to visualize astrocyte activity alongside established biomarkers to further examine the relationship between inflammation and Alzheimer's. If successful, this innovative approach will help deepen our understanding of the underlying disease.' About Neuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by reactive astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]F-DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity (1,2). About Life Molecular Imaging (LMI) Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit About Life Healthcare Group Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: References 1. Nag S, Fazio P, Lehmann L, et al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2016;57(2):315-320. doi:10.2967/jnumed.115.161083 2. Ballweg A, Klaus C, Vogler L, et al. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. J Neuroinflammation. 2023;20(1):68. Published 2023 Mar 11. doi:10.1186/s12974-023-02749-2 For media queries Brittany Hahn | Marketing Communications Manager | Life Molecular Imaging Tel: +1.484.735.2840 | [email protected] For scientific information, please contact: Dr. Gérard N Bischof, PD | Scientific Project Manager | Life Molecular Imaging| [email protected] View original content to download multimedia: SOURCE Life Molecular Imaging
Yahoo
20-05-2025
- Health
- Yahoo
Life Molecular Imaging Secures Funding from the Alzheimer's Drug Discovery Foundation (ADDF) to Further Investigate [18F]F-DED PET in Alzheimer's Neuroinflammation
Joining forces to accelerate development and to create a potential new option for Neuroinflammation Imaging BERLIN and BOSTON, May 20, 2025 /PRNewswire/ -- Life Molecular Imaging has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to advance significant research in Alzheimer's disease (AD). The $2.16 million investment, spanning three years, will fuel the development of [18F]F‑DED, an investigational F18-labeled PET imaging agent designed to target monoamine oxidase B (MAO-B), a key enzyme linked to neuroinflammation. This ambitious research initiative is a collaborative effort with two world-class institutions, including the University Hospital of Ludwig-Maximilian University (LMU; Munich, Germany) and the Barcelona Beta Brain Research Center (BBRC, Spain), with experts in neurology, nuclear medicine, psychiatry, and stroke and dementia research. It is anticipated that using [18F]F-DED PET imaging during this project has the potential to provide critical insights into both sporadic and genetically predisposed AD patients, bridging the gap on the contribution of neuroinflammation between early and late stages of the disease. Until now, PET imaging of neuroinflammation has faced challenges due to genetic polymorphisms affecting ligand binding, leading to inconsistent results. "This new research, supported by the prestigious ADDF funding, provides a unique opportunity to investigate the spatial and temporal dynamics of neuroinflammation and its association with established biomarkers," said Andrew Stephens, Chief Medical Officer at LMI. "Neuroinflammation could be a potential key driver in the spread of tau pathology to the cortex in Alzheimer's disease. Leveraging PET imaging to explore its role presents a unique opportunity to deepen our understanding of disease progression," added Matthias Brendel, Professor for Nuclear Medicine at LMU. Gemma Salvadó Blasco, Group Leader of Neuroimaging Research BBRC, echoed this enthusiasm: "By combining data from diverse Alzheimer's disease cohorts, we aim to unravel the complexities of disease progression. We're thrilled to embark on this exciting journey." "PET-Imaging tools provide important insights into understanding Alzheimer's disease and other neurodegenerative disorders and are integrated now into clinical care," says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. "New imaging tools exploring neuroinflammation may offer a non-invasive approach to visualize astrocyte activity alongside established biomarkers to further examine the relationship between inflammation and Alzheimer's. If successful, this innovative approach will help deepen our understanding of the underlying disease." AboutNeuroinflammation represents a key pathologic mechanism in many neurodegenerative diseases, including AD, movement disorders and multiple sclerosis. In the brain it can be mediated by reactive astrocytes (astrogliosis), which show increased activity of the enzyme monoamine oxidase B (MAO-B). The PET tracer [18F]F-DED is a deuterated deprenyl derivative that was designed to preferentially bind to areas with increased MAO-B activity (1,2). About Life Molecular Imaging (LMI)Life Molecular Imaging (LMI) is an international radiopharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit About Life Healthcare GroupLife Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 40 years' experience in the South African private healthcare sector, and currently operates 64 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, oncology, diagnostic and molecular imaging and health risk management services which include occupational health and wellness services. The Group also owns Life Molecular Imaging, a radiopharmaceutical business dedicated to developing and globally commercializing innovative molecular imaging agents for use in PET-CT diagnostics to detect specific diseases. Visit: About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: References 1. Nag S, Fazio P, Lehmann L, et al. In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. J Nucl Med. 2016;57(2):315-320. doi:10.2967/jnumed.115.161083 2. Ballweg A, Klaus C, Vogler L, et al. [18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. J Neuroinflammation. 2023;20(1):68. Published 2023 Mar 11. doi:10.1186/s12974-023-02749-2 For media queriesBrittany Hahn | Marketing Communications Manager | Life Molecular ImagingTel: +1.484.735.2840 | For scientific information, please contact: Dr. Gérard N Bischof, PD | Scientific Project Manager | LifeMolecular Imaging| View original content to download multimedia: SOURCE Life Molecular Imaging Sign in to access your portfolio
Hamilton Spectator
19-05-2025
- Health
- Hamilton Spectator
Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures
May 19, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United States, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity — without the need for general anesthesia. Designed for procedures such as transcatheter valve repair and left atrial appendage closure, VeriSight Pro offers high-resolution 2D and 3D visualization directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anesthesia and associated risks. 'With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,' said Prof. Dr. Jörg Hausleiter, Ludwig-Maximilians-Universität (LMU) Munich, Germany. 'This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.' Addressing structural heart disease with less burden on patients and hospitals Structural heart disease is a growing challenge across Europe, with increasing volumes of transcatheter valve repair and closure procedures. Today, many of these are supported by transesophageal echocardiography (TEE), which often requires general anesthesia, additional staff, and extended room time. In contrast, 3D ICE imaging provides detailed visualization from within the heart through a catheter introduced via the femoral vein, reducing the need for general anesthesia and recovery time in the Post-Anesthesia Care Unit (PACU), which can shorten hospital stays and lower costs. VeriSight Pro is a pioneering innovation: a miniaturized ultrasound probe, approximately 3 millimeters in diameter, embedded at the tip of a thin, steerable catheter. This tiny device can be navigated through the vascular system and into the heart chambers, where it delivers high-quality 2D and 3D images in real time. Imaging the heart from within, with control over the scan angle, opens entirely new possibilities for guiding structural heart interventions. Physicians can assess anatomy, guide device placement, and confirm procedural results — all from a single access point, and without the need for more invasive imaging techniques. As the first ICE catheter to miniaturize the same 3D imaging technology used in TEE, VeriSight Pro helps address key barriers in delivering efficient, scalable care — from patient tolerance to resource availability in interventional suites. 'VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,' said Stacy Beske, Business Leader of Image-Guided Therapy Devices at Philips. 'Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.' Part of an integrated portfolio for structural heart care VeriSight Pro is part of Philips' structural heart disease ecosystem, seamlessly integrating with Philips' EPIQ ultrasound systems, which in turn integrate with the Azurion image-guided therapy platform. Combined with tools such as EchoNavigator, Philips offers an end-to-end solution for clinicians performing procedures such as tricuspid and mitral valve repair and replacement, atrial septal defect closure, and left atrial appendage occlusion. The catheter's unique features — including xPlane and iRotate technologies — allow physicians to visualize two imaging planes simultaneously and digitally adjust views without physically repositioning the catheter tip. These capabilities enable precise assessment and device deployment with fewer imaging steps. Showcasing 3D ICE in action at EuroPCR 2025 Philips will highlight VeriSight Pro and its role in structural heart interventions at EuroPCR 2025 in Paris, May 20–23. Key activities include: These sessions will offer clinicians an in-depth look at how 3D ICE is being applied in real-world structural heart procedures — from imaging protocols to workflow integration and clinical outcomes. A complete and detailed overview of sessions can be found here: . For further information, please contact: Joost Maltha Philips Global External Relations Tel.: +31 6 10 55 8116 E-Mail: About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at . Attachment
